Alsugeir Dana, Wei Li, Adesuyan Matthew, Cook Sarah, Panay Nicholas, Brauer Ruth
Department of Pharmacy Practice and Policy, UCL School of Pharmacy, London, UK.
Pharmacy Practice Department, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
BJGP Open. 2022 Dec 20;6(4). doi: 10.3399/BJGPO.2022.0126. Print 2022 Dec.
Recent studies on the prescribing of hormone replacement therapy (HRT) medicines to treat symptoms of menopause are lacking.
To describe the prescribing of HRT in a cohort of UK menopausal women.
DESIGN & SETTING: Population-based drug utilisation study using IQVIA Medical Research Database (IMRD-UK).
Primary care data of women with recorded menopause and/or aged ≥50 years between January 2010 and November 2021 were extracted from the database. The incidence rate of women who received their first prescription for HRT was calculated annually using person-years-at-risk (PYAR) as the denominator. Incidence rates of HRT were estimated by type and route of administration. Relative changes in annual incidence rates were expressed as percentages and the average percentage change was assessed using linear regression. Annual prescribing prevalence per 100 women was calculated using mid-year menopausal population estimates.
The incidence rate of prescribing of HRT increased from 5.01 in 2010 to 18.16 per 1000 PYAR in 2021, a relative increase of 13.64% (95% confidence interval [CI] = 6.97 to 20.30) per year. The incidence rate of fixed combinations of HRT increased from 3.33 to 12.23 per 1000 PYAR in 2010 and 2021, respectively. Transdermal formulations of HRT increased from 1.48 to 14.55 per 1000 PYAR in 2010 and 2021, respectively. The overall proportion of women in receipt of a prescription for HRT changed from 7.89% in 2010 to 6.86% in 2020.
This study shows a steady increase in the number of women receiving their first prescription for HRT during the study period, which suggests regained acceptance of HRT medicines.
目前缺乏关于使用激素替代疗法（HRT）药物治疗更年期症状的处方情况的近期研究。
描述英国一群更年期女性的HRT处方情况。
基于人群的药物利用研究，使用艾昆纬医学研究数据库（IMRD - UK）。
从数据库中提取2010年1月至2021年11月期间有更年期记录和/或年龄≥50岁女性的初级保健数据。每年以风险人年（PYAR）为分母计算接受HRT首次处方的女性发病率。按给药类型和途径估计HRT的发病率。年发病率的相对变化以百分比表示，并使用线性回归评估平均百分比变化。每100名女性的年处方患病率使用年中更年期人口估计数计算。
HRT处方的发病率从2010年的每1000 PYAR 5.01增加到2021年的18.16，每年相对增加13.64%（95%置信区间[CI]=6.97至20.30）。HRT固定组合的发病率分别从2010年的每1000 PYAR 3.33增加到2021年的12.23。HRT的透皮制剂分别从2010年的每1000 PYAR 1.48增加到2021年的14.55。接受HRT处方的女性总体比例从2010年的7.89%变为2020年的6.86%。
本研究表明，在研究期间接受HRT首次处方的女性数量稳步增加，这表明HRT药物重新获得了认可。
